House of Representatives
Office of Program Research
Health Care & Wellness Committee
This analysis was prepared by non-partisan legislative staff for the use of legislative members in their deliberations. This analysis is not a part of the legislation nor does it constitute a statement of legislative intent.
Brief Description: Allowing the prescription of a schedule II controlled substance to treat a binge eating disorder.
Sponsors: Senate Committee on Health Care (originally sponsored by Senators Rivers, Keiser, Cleveland, Miloscia and Chase).
Hearing Date: 2/24/16
Staff: Jim Morishima (786-7191).
Authorized prescribers of controlled substances may only prescribe schedule II amphetamines or schedule II non-narcotic stimulants for certain diseases or conditions or under certain circumstances, including for the:
treatment of narcolepsy;
treatment of hyperkinesis;
treatment of drug-induced brain dysfunction;
treatment of epilepsy;
differential diagnosis of depression;
treatment of depression that is refractory to other therapeutic modalities;
treatment of multiple sclerosis; or
clinical investigation of the effects of the drugs.
Summary of Bill:
Authorized prescribers of controlled substances may prescribe schedule II amphetamines or schedule II non-narcotic stimulants for the treatment of binge eating disorder.
Fiscal Note: Requested on February 22, 2016.
Effective Date: The bill takes effect 90 days after adjournment of the session in which the bill is passed.